Table 1.
Experimental and clinical models of the (pro)renin receptor in blood pressure regulation
Experimental studies |
Species | Promoter/Cre | Blood pressure (BP) |
Phenotypic characteristics |
Organ specific effects |
Reference |
---|---|---|---|---|---|---|
Global | ||||||
Over-expression of PRR | Mice | CAG promoter (embryonic stem cells) | No change | Renal expression ↑ 25-80 fold Cardiac expression ↑ 400 fold |
No proteinuria No cardiac dysfunction |
44 |
Over-expression of human PRR | Rats | CAG promoter (embryonic stem cells) | No change | No change | Proteinuria Glomerulosclerosis |
45 |
PRR KO | Mice | ROSA26-creERT2 | Not reported | Early lethality and weight loss | Pathology in colon, bone marrow and liver | 18 |
Kidney | ||||||
Podocyte PRR KO | Mice | podocin-Cre | Not reported | Nephrotic syndrome, early post-natal lethality | Severe renal injury | 16,17 |
HRP in 2-kidney 1-clip Goldblatt | Rat | - | No change | HRP did not change plasma renin or aldosterone levels | No change in cardiac or renal injury | 107 |
PRO20 infusion in inner medulla | Rat | - | ↓ Ang-II infused hypertension (100 ng/kg/min) | - | ↓ proteinuria and glomerulosclerosis following Ang-II | 25 |
PRR shRNA injected to renal medulla | Rat | - | No change | - | Reduced α-ENaC abundance | 31 |
Renal tubule PRR KO | Mice | Pax8-rtTA/LC1- Cre (inducible) | ↓ Ang-II infused hypertension (600 ng/kg/min) | Urinary concentration defect | Reduced α-ENaC abundance | 33 |
CD specific PRR KO | Mice | AQP2-Cre | ↓ Ang-II infused hypertension (300 ng/kg/min) | - | Reduced α-ENaC abundance | 34 |
CD specific PRR KO | Mice | Hoxb7-Cre | ↓ basal systolic BP ↓ Ang-II infused hypertension (400 ng/kg/min) |
Renal hypoplasia and ↓ renal function | Reduced cleaved α-ENaC and γ-ENaC abundance | 35 |
Renal tubule PRR KO | Mice | Pax8-rtTA/LC1- Cre (inducible) | No change in BP with Ang-II infusion (1000 ng/kg/min) | ↑ lysosomal proteins and autophagosome markers | ↓ ability to excrete acid load | 36 |
CD cell specific PRR KO | Mice | AQP2-Cre Principal cell specific | No change in BP | Urinary concentration defect | Reduced α-ENaC abundance | 39 |
CD cell specific PRR KO | Mice | B1-ATPase-Cre Intercalated cell specific | No change in BP | Lower body weight | No change in ENaC abundance | 39 |
Macula densa specific PRR KO | Mice | nNOS/CreERT2 | ↓ BP at baseline and following low Na+ + RAS blocker | ↓ plasma renin concentration | ↓ cyclooxygenase-2 and prostaglandin E synthase | 40 |
Nephron progenitor cells | Mice | Six2GFPCre | Hypertension at 2 months of age | Homozygous deletion – early lethality | ↓ glomeruli number and thickening of basement membrane | 41 |
Cardiovascular system | ||||||
Cardiomyocyte PRR KO | Mice | α MHC-Cre | Not reported | Lethal heart failure within 3 weeks of birth | Autophagic vacuoles in cardiomyocytes | 15 |
Cardiomyocyte specific PRR overexpression | Mice | α MHC promoter | Not reported | 170-fold ↑ PRR mRNA and 5-fold ↑ PRR protein | No change in cardiac function at baseline and following injury | 47 |
Cardiomyocyte specific PRR overexpression | Rats | Adenovirus mediated gene delivery | Not reported | 2-3 fold ↑ PRR protein | ↓ left ventricular ejection fraction | 51 |
Vascular smooth muscle cell PRR KO | Mice | No change in BP | Non-atherogenic sclerosis of aorta | VSMC autophagic cell death | 52 | |
Vascular smooth muscle cell PRR overexpression | Rats | Smooth muscle cell myosin heavy chain gene | Hypertension at 6 months of age | Tachycardia | - | 53 |
Brain | ||||||
Supra-optic nucleus PRR knock-down | Rats (SHR) | Adenovirus mediated gene delivery | ↓ age associated hypertension | ↓ heart rate | ↓ plasma vasopressin levels | 57 |
ICV PRR shRNA infusion | Mice | Overexpressing human renin and angiotensinogen | ↓ BP | ↓ sympathetic tone ↑ baroreflex sensitivity |
↓ Ang-II type 1 receptor and vasopressin levels in brain | 58 |
Neuron specific PRR KO | Mice | Nefh-Cre | ↓ BP in ICV infusion of prorenin/ DOCA-salt | ↓ sympathetic tone ↑ baroreflex sensitivity |
↓ brain Ang-II levels | 20 |
ICV PRO20 infusion | Mice | - | ↓ BP Ang-II and DOCA-salt hypertension | ↓ sympathetic tone ↑ baroreflex sensitivity |
↓ brain hypothalamic Ang- II levels with DOCA-salt | 6 |
Adipose tissue | ||||||
Adipose tissue PRR KO | Mice | Adiponectin-Cre | ↑ BP at baseline and following high fat diet | Lipodystrophy | ↑ plasma sPRR | 21 |
Clinical Studies | Species | Controls | Blood pressure | Other pertinent findings | ||
Pre-eclamptic women | Human | Normotensive pregnant women | ↑ BP | ↑ placental PRR and ↑ plasma sPRR BP correlated with placental PRR but not plasma sPRR | 67 | |
Pre-eclamptic and diabetic women | Human | Healthy pregnant controls | Not reported | ↑ plasma sPRR in diabetes but not preeclamptic or healthy controls | 68 | |
Japanese cohort of 1100 participants | Human | - | ↑ BP in men with IVS5+169C > T polymorphism | - | 69 | |
Caucasian cohort | Human | - | ↑ BP in men with IVS5+169C > T polymorphism | - | 70 |
KO - knock out; Ang-II – Angiotensin-II; ENaC – epithelial Na channel; RAS – renin angiotensin system blocker; ICV – intracerebroventricular; sPRR- soluble PRR; DOCA-salt – Deoxycorticosterone acetate;